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Abstract Atopic dermatitis (AD) is a chronic, recurrent,
inflammatory skin disease which predominantly affects
children. However, AD may persist until adulthood (per-
sistent AD), or directly start in adults (adult-onset AD). AD
often shows a non-flexural rash distribution, and atypical
morphologic variants in adults and specific diagnostic cri-
teria are lacking. Moreover, adult AD prevalence as well as
detailed data which can characterize persistent vs adult-
onset subtype are scant. The aim of this study was to
investigate on the main features of adult AD particularly
highlighting differences between persistent vs adult-onset
form. An Italian multicentre observational study was con-
ducted between April 2015–July 2016 through a study-
specific digital database. 253 adult AD patients were
enrolled. Familiar history of AD was negative in 81.0%.
Erythemato-desquamative pattern was the most frequent
clinical presentation (74.3%). Flexural surface of upper
limbs was most commonly involved (47.8%), followed by
eyelid/periocular area (37.9%), hands (37.2%), and neck
(32%). Hypertension (7.1%) and thyroiditis (4.3%) were
the most frequent comorbidities. A subgroup analysis
between persistent (59.7%) vs adult-onset AD patients
(40.3%) showed significant results only regarding AD
severity (severe disease was more common in persistent
group, p\ 0.05), itch intensity (higher in adult-onset dis-
ease), and comorbidities (hypertension was more frequent
in adult-onset group, p\ 0.01). Adult AD showed
uncommon features such as significant association with
negative AD family history and lacking of association with
systemic comorbidities respect to general population. No
significant differences among persistent vs adult-onset
subgroup were registered except for hypertension, itch
intensity, and disease severity.
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Introduction
Atopic dermatitis (AD) is a chronically recurrent, pruritic,
inflammatory skin disease which predominantly affects
children, usually clearing up during infancy or childhood
[20, 35]. However, AD may persist with a chronic relaps-
ing course until adulthood (persistent AD), possibly being
recalcitrant to different treatments [34]. On the other hand,
in some patients, AD directly starts later in life (i.e., after
18 years of age), the so-called adult-onset AD [7]. Adult
AD has a major impact on quality of life and working
abilities [20]. Since the frequency of AD is constantly
increasing worldwide [3], it is also conceivable that both
prevalence and incidence of adult AD are rising [3], even if
detailed data are lacking; indeed, studies show very vari-
able results, reporting that AD may affect 0.3–14.3% of the
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adult population [3, 12, 13, 19, 20, 22, 27]. Specific diag-
nostic criteria for adult AD are not available and those used
for pediatric patients (Hanifin and Rajka as well as UK
criteria above all [4]) have been only adapted to adults,
with a consequent reduction of specificity and sensitivity;
e.g., in approximately one-fourth of patients, the diagnosis
of adult-onset AD was not possible according to UK cri-
teria in its current form [20, 22]. Adult AD diagnosis is also
complicated by the fact that in adult patients, AD often
shows a non-flexural rash distribution and atypical mor-
phologic variants, such as nummular or prurigo-like lesions
[20]. Moreover, literature is constantly enriching of surveys
which show adult AD as a possible systemic disease, being
associated with metabolic and cardiovascular comorbidi-
ties [25, 26, 29, 37]. However, the possible correlation of
these comorbidities with AD clinical and morphological
forms, persistent vs adult-onset type, as well as the pres-
ence of non-cutaneous atopic manifestations have not been
investigated so far. Moreover, data regarding systemic
treatment effectiveness and long-term safety in adult
patients with AD are insufficient and therapy approach
widely differs among diverse countries [18]. Despite all
these unmet needs, studies on adult AD are still scant;
nevertheless, different new treatments for adult AD will be
available in the next future [9, 28]. In the current study, we
reported the results of an Italian multicentre study on adult
AD, highlighting eventual differences on clinical features,
involved body sites, past and present medical history, as
well as previous and ongoing AD treatments between
persistent and adult-onset AD group. This analysis also
performed a general overview on adult AD trying to put the
basis for the development of specific adult AD diagnostic
criteria.
Materials and methods
A multicentre observational study involving 14 dermato-
logical reference centers (mainly university departments)
located throughout Italy was conducted between April
2015 and July 2016.
Patients referring to each participating centre were con-
secutively enrolled. Inclusion criteria were: (1) diagnosis of
atopic dermatitis by a high experienced dermatologist
(C15 years) (basing on clinical features, and/or medical
history, and/or histological examination, and/or treatment
response); (2) disease duration C6 months; (3) patients’
age C18 years. Exclusion criteria were: the presence of
current other exogenous and/or endogenous dermatoses,
paying particular attention to the most common adult AD
stimulants such as allergic contact dermatitis, cutaneous
T-cell lymphoma, seborrheic dermatitis, lichen simplex
chronicus, and prurigo nodularis. For each patient, the
following data were registered in a study-specific digital
database using electronic case report forms expressly created
to store adult AD characteristics (http://www.dermatiteato
picadulto.it): (1) personal and demographic data; (2) AD past
and current history; (3) previous topical and/or systemic AD
treatments; (4) current topical and/or systemic treatments;
and (5) concomitant diseases Particularly, AD past and
current history section explored AD age of onset, family
history of AD, personal medical history of atopy (asthma,
allergic conjunctivitis, and allergic rhinitis), localization and
morphology of AD lesions, AD severity, and pruritus
intensity measured through a visual analogue scale (VAS)
ranging from 0 to 10 (where ‘‘0’’ means ‘‘doesn’t itch at all’’
and ‘‘10’’ means ‘‘itch is worse than ever’’). As regards the
classification of AD lesions morphology, erythemato-
desquamative, lichenified, exudative, and diffuse xerosis
patterns were chosen. Since adult AD patients may fre-
quently show mixed skin lesions patterns, in each patient,
AD morphology was classified following most common
clinical aspect (C50% of existing lesions). AD severity was
registered as mild [scoring atopic dermatitis index
(SCORAD)\24 and/or objective SCORAD\15 and/or
three-item severity score (TIS)\3)], moderate (SCORAD
25–50 and/or objective SCORAD 15–40 and/or TIS 3–6), or
severe (SCORAD[50 and/or objective SCORAD[40 and/
or TIS C6) [33, 35]; each patient signed a written consent
form to participate in the study. The study was approved by
local ethics committee for every survey participating site and
performed in line with declaration of Helsinki guidelines.
Statistical analysis
Fisher’s exact test was used for statistical analysis. p val-
ues\0.05 were considered statistically significant. All the
statistical analyses were performed using GraphPad Prism
4.0 (GraphPad Software Inc., La Jolla, USA).
Results
Persistent vs adult-onset AD
Personal and demographic data
In our study population, persistent AD (onset\18 years of
age) was more common than adult-onset disease (on-
set C18 years of age). Indeed, 59.7% (151/253) of patients
suffered from persistent AD, whereas in 40.3% (102/253),
AD had directly started in adult age (Table 1). Male sex
was most frequently affected in both groups, however,
without approaching statistical significance (51.6 and
60.8% of males in persistent and adult-onset group,
respectively) (Table 1). Significant higher subjects mean
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Table 1 Persistent AD vs adult-onset AD group
Feature Persistent AD group n (%) Adult-onset AD group n (%) p
Number 151 102
Sex
Male 78 (51.6) 62 (60.8) 0.89
Female 63 (48.4) 50 (49.2)
Mean age (years) ± sd 31.9 ± 11.6 36.5 ± 12.4 \0.05
Patient residence
Rural 28 (16.6) 27 (29.4) 0.22
Urban 126 (83.4) 72 (70.6)
Personal history of non-cutaneous atopic disease 80 (50.3) 52 (48) 0.91
Asthma 37 (24.5) 28 (27.5) 0.77
Allergic conjunctivitis 36 (23.8) 29 (26.5) 0.57
Allergic rhinitis 72 (47.7) 46 (45.1) 0.82
Family history of AD
Positive 29 (19.2) 19 (18.6) 1
Negative 122 (80.8) 83 (81.4)
AD severity
Mild 64 (42.4) 62 (60.8) 0.12
Moderate 59 (39.1) 32 (31.4) 0.45
Severe 28 (18.5) 8 (7.8) \0.05
Main morphology of skin lesion
Erythemato-desquamative 118 (78.1) 70 (68.6) 0.55
Lichenified 21 (13.9) 20 (19.6) 0.31
Diffuse xerosis 7 (4.6) 8 (7.9) 0.41
Exudative 5 (3.3) 4 (3.9) 1
Pruritus intensity 4.6 ± 2.5 6.2 ± 2.3 \0.05
(VAS score 0-10: mean ± SD)
Previous treatments
Topical
Corticosteroids 121 (80.1) 75 (73.5) 0.69
Emollients 108 (71.5) 70 (68.6) 0.84
Pimecrolimus 12 (7.9) 5 (4.9) 0.44
Tacrolimus 25 (16.5) 14 (13.7) 0.72
Other 3 (2) 1 (0.9) 0.65
Systemic
Azathioprine 1 (0.7) 0 (0) 1
Corticosteroids 58 (38.4) 34 (33.3) 0.61
Cyclosporine 18 (11.9) 11 (10.8) 0.84
Methotrexate 2 (1.3) 0 (0) 0.51
NB-UVB phototherapy 24 (15.9) 6 (5.9) \0.05
Omalizumab 1 (0.7) 0 (0) 1
UVA phototherapy 5 (2.4) 1 (0.9) 0.4
Other 29 (19.2) 11 (10.8) 0.16
Current treatments
Topical
Corticosteroids 71 (47) 34 (33.3) 0.18
Emollients 92 (60.9) 66 (64.7) 0.83
Pimecrolimus 4 (2.6) 5 (4.9) 0.49
Tacrolimus 9 (6) 6 (5.9) 1
Other 0 (0) 2 (1.9) 0.16
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age was registered in AD adult-onset group respect to
persistent AD one (36.5 ± 12.4 years vs 31.9 ± 11.6,
p\ 0.05). Urban residence prevailed respect rural one in
both groups (see Table 1 for details).
AD past and current history
No significant differences were found for positive personal
history of atopy which was present in almost 50% of
subjects in both groups; allergic rhinitis was reported as the
most frequent non-cutaneous atopic manifestation in both
groups (72/151, 47.7% of persistent AD patients vs 46/102,
45.1% of adult-onset AD subjects) (Table 1).
Similar results were observed for positive family history
of AD which was negative in 80.8% (122/151) of persistent
AD subjects and 81.4% (83/102) of adult-onset AD
patients.
As regards morphology of AD lesions, no differences
were found: erythemato-desquamative pattern was the
most common clinical presentation in both groups (118/
151, 78.1% in persistent AD group and 70/102, 68.6% in
adult-onset AD), followed by lichenified pattern (21/151,
13.9 vs 20/102, 19.6%). Exudative pattern was registered
as the less frequently observed being reported in only 3.3%
(5/152) and 3.9% (4/102) of persistent and adult-onset
disease group, respectively (Table 1). No statistically sig-
nificant differences were found regarding AD lesion
localization between persistent and adult-onset AD group.
Flexural region of upper limbs was reported as the most
commonly affected site (44/102, 43.1 vs 77/151, 51%, in
adult AD and persistent group, respectively), followed by
eyelid—periocular area (33/102, 32.4 vs 63/152, 41.7%),
hand (dorsal surface) (36/102, 35.5 vs 58/152, 38.4%),
neck (26/102, 25.5 vs 55/151, 36.4%), and labial—perioral
area (22/102, 21.6 vs 53/151, 35%). Conversely, plants (2/
102, 1.9 vs 2/151, 1.3%), elbow (5/102, 4.9 vs 12/151,
7.9%), knee (6/102, 5.9 vs 13/151, 8.6%), and scalp (7/102,
6.9 vs 12/151, 7.9%) were the less frequently involved
body areas in both groups (data not shown).
Analyzing AD severity, a higher percentage of patients
with mild disease was found in the adult-onset AD group
compared to the persistent AD group (62/102, 60.8 vs
64/151, 42.4%), whereas opposite results were observed for
patients with severe disease (8/102, 7.8 vs 28/151, 18.5%),
Table 1 continued
Feature Persistent AD group n (%) Adult-onset AD group n (%) p
Systemic
Azathioprine 3 (2) 1 (0.9) 0.65
Corticosteroids 9 (6) 5 (4.9) 0.78
Cyclosporine 6 (4) 4 (3.9) 1
Methotrexate 0 (0) 0 (0) 1
NB-UVB phototherapy 13 (8.6) 7 (6.9) 0.81
Omalizumab 0 (0) 0 (0) 1
UVA phototherapy 0 (0) 0 (0) 1
Other 14 (5.5) 6 (5.9) 0.47
Comorbidities
Celiac disease 2 (1.3) 1 (1) 1
Coronary artery disease 0 (0) 3 (2.9) 0.06
Diabetes 1 (0.7) 2 (2) 0.3
Hypercolesterolemia 2 (1.3) 4 (3.9) 0.23
Hypertension 4 (2.6) 14 (13.7) \0.01
Hypertriglyceridemia 0 (0) 3 (2.9) 0.06
Obesity 2 (1.3) 2 (2) 1
Stroke 0 (0) 1 (1) 0.4
Thyroiditis 4 (2.6) 7 (6.9) 0.2
Other 6 (4) 7 (6.9) 0.39
Cutaneous comorbidities
Contact sensitization 10 (6.6) 9 (8.8) 0.63
Psoriasis 4 (2.6) 6 (5.9) 0.32
Vitiligo 1 (0.7) 0 (0) 1
Other 4 (2.6) 1 (1) 0.65
SD standard deviation; VAS visual analogue scale
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even if results reached statistical significance only for
severe disease (p\ 0.05).
Pruritus intensity was significantly higher in adult-onset
group respect persistent one (6.2 ± 2.3 vs 4.6 ± 2.5,
p\ 0.05).
Previous topical and/or systemic AD treatments
Emollients and corticosteroids were the most common pre-
vious topical treatments in both groups (from 68.6 to 80.1%
of subjects, Table 1). As regards systemic treatments, brief
course of systemic corticosteroids was the most frequently
prescribed (58/151, 38.4 vs 34/102, 33.3%, Table 1). There
was not any significant differences between persistent vs
adult-onset AD except for narrow band (NB)-UVB which
was more common in persistent AD past medical history (24/
151, 15.9 vs 6/102, 5.9%, p\ 0.05).
Current topical and/or systemic treatments
Emollients were the main ongoing topical treatment in both
groups (92/151, 60.9 vs 66/102, 64.7%), followed by
topical corticosteroids (71/151, 47 vs 34/102, 33.3%),
whereas NB-UVB prevailed among the systemic therapies
(13/151, 8.6 vs 7/102, 6.9%) in persistent and adult-onset
AD group (Table 1). The comparison between ongoing
treatments did not show any statistically significant dif-
ferences between persistent and adult-onset AD.
Concomitant diseases
Comorbidities were much more frequent in the adult-onset
AD group respect to persistent AD group; particularly, this
trend was registered for coronary artery disease, hyper-
tension, hypercholesterolemia, hypertriglyceridemia, and
autoimmune thyroiditis with statistical significance reached
only by hypertension (4/151, 2.6 vs 14/102, 13.7%;
p\ 0.01). However, hypertriglyceridemia and coronary
artery disease almost approached statistical significance (0/
151, 0 vs 3/101, 2.9%, p = 0.06 in both cases. The rate of
skin diseases linked to AD was comparable between the
two groups. Contact sensitization and psoriasis were the
most common in both groups (Table 1). Particularly, as
regard contact sensitization, involved haptens are displayed
in Table 2; no significant differences were observed
between persistent and adult-onset disease group.
Total adult AD study population analysis
Personal and demographic data
The study population consisted of 253 adult AD patients
[140 male (55.3%) and 113 female (44.7%), mean age
33.8 ± 14.8 years] (Table 3). Gender did not appear to be
a relevant marker of AD in adults. Mean age of AD onset
was 16.2 ± 18.8 years. Patients residence was more com-
monly urban than rural (198/253, 78.3 vs 55/253, 21.7%).
AD past and current history
A positive personal history of non-cutaneous atopic disease
was present in half of the patients (132/253, 52.2%); par-
ticularly 65/253 (25.7%) patients suffered from asthma,
65/253 (25.7%) from allergic conjunctivitis, and 118/253
(46.6%) from allergic rhinitis, which was hence observed
as the most common atopic manifestation linked to adult
AD. Interestingly, 81% (205/253) of subjects presented a
negative familiar history of AD.
As regards principal AD features, the main clinical
morphology of AD lesions was represented by erythemato-
desquamative pattern (188/253, 74.3%), followed by
lichenified one (41/253, 16.2%); exudative lesions were the
less frequently registered (10/253, 4%) (Table 3). AD
lesions more frequently involved the flexural surface of
upper limbs (121/253, 47.8%), followed by eyelid and
periocular area (96/253, 37.9%), hands (dorsal surface)
(94/253, 37.2%), neck (81/253, 32%), and labial and
perioral area (75/253, 29.6%) (see Fig. 1 for detailed data
regarding skin lesions localization).
Analyzing global disease severity, it was rated as mild in
125/253 (49.4%), moderate in 91/253 (36%), and severe in
37/253 (14.6%) of cases. In general, itch was a frequent
symptom in adult AD patients with a mean VAS-pruritus
intensity was 5.8 ± 2.87.
Previous topical and/or systemic AD treatments
Obviously, topical corticosteroids and emollients resulted
as the mainstay of previous treatments, being reported by
196/253 (77.5%) and 178/253 (70.3%) patients, respec-
tively, followed by brief course of systemic corticosteroids
(92/253, 36.4%).
Current topical and/or systemic AD treatments
Topical emollients were reported as the most common
ongoing therapy (158/253, 62.4%), followed by topical
corticosteroids (105/253, 41.5%) and NB-UVB photother-
apy (20/253, 7.9%) (Table 3).
Concomitant diseases
Obesity was not frequent in our group of patients (4/253,
1.6%), with hypertension and autoimmune thyroiditis being
the most frequent reported comorbidities (18/253, 7.1 and
11/253, 4.3% respectively) (Table 3). Not surprisingly,
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contact sensitization was registered as the principal skin
disease associated with adult AD (7.5%); psoriasis was
observed in 10/253 (4%) of adult AD patients.
Discussion
AD lifetime prevalence has shown a worldwide increase in
the past 30 years, seeming to reach a plateau at 10–20% in
developed countries, whereas it continues to increase in
many developing countries [5, 32]. AD usually starts dur-
ing the first year of age (up to 60% of cases), but it may
begin at any age [7, 10]. Several studies have suggested
that AD may greatly improve or disappear until late
childhood in up to 70% of cases, with early and severe
onset, family history of AD, and early allergen sensitiza-
tions being risk factors for a longer course [10, 23].
Therefore, it is not surprising that adult AD prevalence is
rising worldwide even if detailed data are still lacking;
indeed, studies show very variable results, reporting that
AD may affect 1–10% of the adult population, with find-
ings from pediatric registries suggesting that the prevalence
of persistent or adult-onset disease is underestimated and
higher than previously assumed [3, 12, 13, 17, 19, 20, 22].
Therefore, we conducted an Italian multicentre study on
adult AD enrolling 253 subjects. Surprisingly, even if
positive family history of AD is commonly reported as a
risk factor for persistent AD [10, 23], it was found in only
19% (48/253) of adult AD patients suggesting that it could
be less important respect to childhood AD where a positive
family history of the disease is generally reported in
54.2–68% of cases [8, 14]. Therefore, it may be suggested
that adult-onset AD form did not tend to show a significant
association with positive AD family history respect to
classical AD of childhood. Our findings are only partially
in line with the previous studies which report variable
percentages of positive family history of AD (17–35%) in
adult AD patients [2, 6, 22, 31]. However, we believe that
this hypothesis needs to be further investigated and
eventually confirmed in future studies, also because a sub-
analysis between persistent AD and adult-onset AD group
did not reveal significant difference in positive AD family
history percentage (19.2 vs 18.6%). Moreover, it should
also be stated that this result may be influenced by possible
uncorrected personal medical history (AD patients are not
always able to remember their infantile or early AD,
especially in mild cases). As regards AD skin lesions
morphology, erythemato-desquamative skin manifestations
were the most commonly observed (188/253, 74.3%), fol-
lowed by lichenified lesions (41/253, 16.2%), diffuse
xerosis (14/253, 5.5%), and exudative lesions (10/253,
4%). No differences were found between persistent AD and
adult-onset AD sub-groups of patients (Table 1). Interest-
ing data came from the analysis of AD skin lesions local-
ization (Fig. 1). Flexural region of upper limbs was the
body area most frequently involved (121/253, 47.8%),
supporting the results of previous studies which proposed
flexural area involvement as one of the main possible
important criteria for adult AD identification [14, 22].
Other frequently involved areas were represented by eyelid
and periocular area (96/253, 37.9%), hands (dorsal surface)
(94/253, 37.2%), neck (81/253, 32%), and labial and
perioral area (75/253, 29.6%). Particularly, the common
involvement of hands in adult AD patients was also sup-
ported by the previous investigations [2, 11, 14] as the case
of eyelid/periocular, neck and labial/perilabial lesions
predominance [36], appearing as interesting data which
may guide future research trying to establish adult AD-
specific diagnostic criteria. Indeed, diagnostic criteria
usually used (Hanifin and Rajka and UK criteria) are not
completely adaptable in adult patients with a consequent
reduction of specificity and sensitivity [14, 20, 22]. Per-
sistent and adult-onset AD did not present any significant
differences regarding skin lesions localizations (data not
shown), suggesting that separate clinical diagnostic criteria
for these two adult AD forms may not be needed. Finally,
as concerns AD severity, there were no significant differ-
ences between persistent vs adult-onset AD except for
severe disease which was more common in persistent AD
group; however, mild disease was the most common form
in both groups, followed by moderate disease and severe
forms, confirming the results of Kulthanan et al. [14].
Patients with childhood AD often have personal and/or
family history of other atopic diseases such as asthma,
allergic rhinitis, and allergic conjunctivitis [24]. This
strong association is confirmed also in adult AD subjects.
Half (132/253, 52.2%) of our study population showed a
personal history of atopic diseases with allergic rhinitis
being the most commonly observed (118/253, 46.6%), in
line with the previous studies [14]. No differences were
found between the subset of persistent vs adult-onset adult
AD forms. It has been proposed that AD is a systemic
Table 2 Contact sensitization in persistent vs adult-onset AD group
Hapten Persistent AD
group n (%)
Adult-onset AD
group n (%)
p
Balsam of Peru 2 (1.3) 1 (0.9) 1
Cobalt 0 (0) 1 (0.9) 1
Corticosteroids 1 (0.7) 0 (0) 1
Fragrance mix 2 (1.3) 1 (0.9) 1
Kathon CG 2 (1.3) 1 (0.9) 1
Nickel 3 (0) 2 (1.9) 1
Para-phenylenediamine 0 (0) 1 (0.9) 1
Potassium dichromate 0 (0) 1 (0.9) 1
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disease where the skin manifestations are only a part of the
disorder [16, 25, 26, 37]. Therefore, we also focused on
evaluating the possible presence of systemic as well as skin
comorbidities in adult AD patients. Our results showed that
hypertension was the most frequent systemic comorbidity
in adult AD patients (18/253, 7.1%) followed by autoim-
mune thyroiditis (11/253, 4.3%). Hypertension appeared
also to be more associated with adult-onset than persistent
AD (14/102, 13.7 vs 4/151, 2.6%; p\ 0.01). However, it
should be stated that adult-onset group showed a higher
mean age respect to persistent AD, possibly influencing the
frequency of systemic comorbidities. Conversely, obesity
was very uncommon, being found in only 4/253 (1.6%) of
subjects. This finding did not confirm the previous studies
which showed that obesity was associated with AD in
adults [25, 37], supporting the results of Sybilski et al.
which reported obesity as a risk factor for asthma but not
for AD in a cohort of 18,617 subjects [30]. Further studies
are needed to deeply clarify this relationship, since
Table 3 Main features of the study population
Feature Study population
n (%)
Number 253 (100)
Sex
Male 140 (55.3)
Female 113 (44.7)
Mean age (years) ± sd 33.8 ± 14.8
Patient residence
Rural 55 (21.7)
Urban 198 (78.3)
Personal history of non-cutaneous atopic
disease
132 (52.2)
Asthma 65 (25.7)
Allergic conjunctivitis 65 (25.7)
Allergic rhinitis 118 (46.6)
Familiar history of AD
Positive 48 (19)
Negative 205 (81)
AD severity
Mild 125 (49.4)
Moderate 91 (36)
Severe 37 (14.6)
Main morphology of skin lesion
Erythemato-desquamative 188 (74.3)
Lichenified 41 (16.2)
Diffuse xerosis 14 (5.5)
Exudative 10 (4)
Pruritus intensity (VAS score 0-10:
mean ± SD)
5.8 ± 2.87
Previous treatments
Topical
Corticosteroids 196 (77.5)
Emollients 178 (70.3)
Pimecrolimus 17 (6.7)
Tacrolimus 39 (15.4)
Other 4 (1.6)
Systemic
Azathioprine 1 (0.4)
Corticosteroids 92 (36.4)
Cyclosporine 29 (11.5)
Methotrexate 2 (0.8)
NB-UVB phototherapy 30 (11.9)
Omalizumab 1 (0.4)
UVA phototherapy 6 (2.4)
Other 40 (15.8)
Current treatments
Topical
Corticosteroids 105 (41.5)
Emollients 158 (62.4)
Pimecrolimus 9 (3.6)
Table 3 continued
Feature Study population
n (%)
Tacrolimus 15 (5.9)
Other 2 (0.8)
Systemic
Azathioprine 4 (1.6)
Corticosteroids 14 (5.5)
Cyclosporine 10 (4)
Methotrexate 0 (0)
NB-UVB phototherapy 20 (7.9)
Omalizumab 0 (0)
UVA phototherapy 0 (0)
Other 20 (7.9)
Comorbidities
Celiac disease 3 (1.2)
Coronary artery disease 3 (1.2)
Diabetes 3 (1.2)
Hypercolesterolemia 6 (2.4)
Hypertension 18 (7.1)
Hypertriglyceridemia 3 (1.2)
Obesity 4 (1.6)
Stroke 1 (0.4)
Thyroiditis 11 (4.3)
Other 13 (5.1)
Cutaneous comorbidities
Contact dermatitis 19 (7.5)
Psoriasis 10 (4)
Vitiligo 1 (0.4)
Other 4 (1.6)
SD standard deviation; VAS visual analogue scale
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literature is constantly enriching of surveys showing dif-
ferent and debatable results like the very recent cross-
sectional study with a nationwide sample of the Korean
population conducted by Lee et al. which suggested that
obesity was related to AD in adult women, but not in men
[15]. As regards skin comorbidities, it is not surprisingly
that contact sensitization was found in 19/253 (7.5%) of
adult AD subjects, being, therefore, frequent in this class of
patients as previously suggested [11, 14]. Interestingly,
psoriasis, a Th1–Th17-mediated disease [1], was found in
4% of our patients (10/253), a percentage which is similar
to the psoriasis prevalence in general population, suggest-
ing a possible overlap between Th1–Th17 and Th-2 path-
ways in AD, especially in adult-onset or persistent chronic
forms as reported by a study conducted among Korean
adults visiting health service centre in Seul [13]. Indeed,
the importance of Th1–Th17 pathway in AD course is
further supported by a very recent study which showed that
the profile of Cutaneous Mesenchymal Stem Cells,
obtained from patients suffering from chronic AD, retraces
a Th1–Th17 environment [up-regulation of interleukin
(IL)6, IL8, IL12, IL13, IL17A, IL17F, transforming growth
factor-b, interferon-c, whereas Th2 chemokines such as
IL2, IL4, IL5, and IL23A were down-regulated) [21].
In conclusion, epidemiological and clinical studies on
adult AD are still poor. We have performed an Italian
multicentre pilot study on adult AD patients reporting that
persistent and adult-onset AD did not show substantial
differences except for disease severity (severe disease was
more common in persistent AD group), pruritus intensity
(higher in adult-onset disease), and comorbidities (hyper-
tension was more frequent in adult-onset group with also
hypertriglyceridemia and coronary artery disease almost
approaching significance). Further research with greater
study population is needed to deeply study the epidemio-
logical and clinical features of adult AD, underline even-
tual differences between adult-onset and persistent AD
subset, and to put the basis to establish specific adult AD
diagnostic criteria.
Our study showed some limitations such as the rela-
tively small sample size which may limit the generaliz-
ability of the results and the comparison between adult-
onset vs persistent AD groups particularly regarding the
frequency of comorbidities.
Fig. 1 AD lesion localization in the study population
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